Ivonescimab clinical trials
Also written AK112 and SMT112.
How each study uses ivonescimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ivonescimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
142 studies that test it; most in 2025 (59); 4 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 9 |
| 2023 | 8 |
| 2024 | 21 |
| 2025 | 59 |
| 2026 | 37 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 47 · Other 99
Akeso (38) · M.D. Anderson Cancer Center (9) · Sun Yat-sen University (8) · Fudan University (6) · Summit Therapeutics (5) · Memorial Sloan Kettering Cancer Center (5) · Tianjin Medical University Cancer Institute and Hospital (4) · Peking University Cancer Hospital & Institute (3)
Often tested with
Tested in the same studies.
Cadonilimab (8) · Docetaxel (6) · Ligufalimab (5) · Paclitaxel (4) · Gemcitabine (4) · Albumin-Bound Paclitaxel (3) · Trastuzumab rezetecan (3) · Irinotecan sucrosofate (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 46, 5 in phase 3
Studies that test ivonescimab, phase 3 first.
- Dec 2026AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerPhase 3 · Akeso
- Jan 2027A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Phase 3 · Akeso
- Jan 2027AK112 and Chemotherapy in First-line Metastatic Colorectal CancerPhase 3 · Akeso
- May 2027Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerPhase 3 · Akeso
- May 2027A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerPhase 3 · Akeso
- Dec 2026Study of AK119 Combined With AK112 in Patients With Advanced Solid TumorsPhase 1/2 · Akeso
- Dec 2026Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAPhase 2 · Massachusetts General Hospital
- Dec 2026Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II TrialPhase 2 · Sun Yat-sen University
- Dec 2026A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerPhase 2 · Akeso
- Dec 2026AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerPhase 1/2 · Akeso
Studies
Open first, then newest update. How each study uses ivonescimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 146
- Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell CarcinomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06567314Written as Ivonescimab
- Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT06959550Written as Ivonescimab
- Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerRecruitingPhase 3Summit TherapeuticsNCT07228832Written as Drug: Ivonescimab Injection
- A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2MedSIRNCT07917481Written as Ivonescimab
- Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural MesotheliomaRecruitingPhase 1/2Ruijin HospitalNCT07885319Written as Ivonescimab Combined With Chemotherapy
- Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLCRecruitingPhase 2Swiss Cancer InstituteNCT07158489Written as Gemcitabine + Ivonescimab
- Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)RecruitingPhase 2Guangdong Provincial People's HospitalNCT07472478Written as Ivonescimab Combined With Chemotherapy
- Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell CancerRecruitingPhase 2City of Hope Medical CenterNCT07226544Written as Ivonescimab
- A Study of Ivonescimab in People With LeiomyosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07516925Written as Ivonescimab
- A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland CancersRecruitingPhase 2Dana-Farber Cancer InstituteNCT06805617Written as Ivonescimab
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerNot yet recruitingPhase 2Summit TherapeuticsNCT07877194Written as Ivonescimab (dose level 1) combined with Cadonilimab
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT07393555Written as Ivonescimab
- Ivonescimab for the Treatment of Thymic CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT06980077Written as Ivonescimab
- A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract CancerRecruitingPhase 2Haitao Zhao, MDNCT07854600Written as Ivonescimab
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)RecruitingPhase 1/2GlaxoSmithKlineNCT07602855Written as Ivonescimab
- A Study of Ivonescimab in People With Endometrial and Cervical CancersRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06925724Written as Ivonescimab
- STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)Not yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07743138Written as Ivonescimab
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1RecruitingPhase 3Summit TherapeuticsNCT06767514Written as Ivonescimab Injection
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07619339Written as Ivonescimab
- Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLCNot yet recruitingPhase 2Shaodong HongNCT07819591Written as Ivonescimab
See all 146 studies that test ivonescimab →
Given beside what is tested · 21 — ivonescimab is usual care or a partner of the new treatment
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Written as Ivonescimab
- A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid TumorsRecruitingPhase 1AkesoNCT06929663Written as AK112 Injection
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338Written as Ivonescimab
- A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung CancerNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07899086Written as Ivonescimab
- Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC PatientsNot yet recruitingPhase 1Everest Medicines (Beijing) Co., Ltd.NCT07614646Written as Ivonescimab
- Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBCNot yet recruitingPhase 2University of Kansas Medical CenterNCT07743632Written as Ivonescimab
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerRecruitingPhase 1/2AkesoNCT07623356Written as Ivonescimab
- A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast CancerRecruitingPhase 2AkesoNCT07591090Written as AK112 Injection
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07535437Written as Ivonescimab
- A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07208773Written as Ivonescimab
- A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial CarcinomaNot yet recruitingPhase 2AkesoNCT07636772Written as AK112 Injection
- Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.Not yet recruitingPhase 2Shanghai Allink Biotherapeutics Co., Ltd.NCT07603791Written as Ivonescimab Injection
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast CancerNot yet recruitingPhase 1/2AkesoNCT07560124Written as Ivonescimab
- Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal AdenocarcinomaRecruitingPhase 2UNICANCERNCT06846346Written as Ivonescimab
- Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCRecruitingPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06868732Written as Ivonescimab
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingPhase 2AkesoNCT07052253Written as AK112
- First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant TumorsRecruitingPhase 1/2Shanghai JMT-Bio Inc.NCT06877650Written as Ivonescimab
- Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical CancerNot yet recruitingPhase 2Women's Hospital School Of Medicine Zhejiang UniversityNCT07244965Written as Ivonescimab Combined With Chemotherapy
- Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal MetastasisRecruitingPhase 1/2Guangzhou Medical UniversityNCT06809517Written as AK112
- Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT06957561Written as Ivonescimab(AK112,a PD-1/VEGF bispecific antibody)
Showing 20 of 21.
As the comparator · 1 — what is tested is compared with ivonescimab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
- Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural MesotheliomaOct 26, 2026NCT07885319
- Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)Oct 23, 2026NCT07472478
Newly registered3
- A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular CarcinomaNov 4, 2026NCT07917481
- Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural MesotheliomaOct 21, 2026NCT07885306
- Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural MesotheliomaOct 21, 2026NCT07885319
Codes
What other systems call ivonescimab · ClinicalTrials.gg INT018524
- UNII (FDA) Y0O332CU66IVONESCIMABOne source FDA
- NCI Thesaurus C184865IvonescimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y0O332CU66 | IVONESCIMAB | One source FDA |
| NCI Thesaurus | C184865 | Ivonescimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.